Expression of epidermal growth factor (EGF)/transforming growth factor-α by human lung cancer cells determines their response to EGF receptor tyrosine kinase inhibition in the lungs of mice

@article{Wu2007ExpressionOE,
  title={Expression of epidermal growth factor (EGF)/transforming growth factor-$\alpha$ by human lung cancer cells determines their response to EGF receptor tyrosine kinase inhibition in the lungs of mice},
  author={Wenjuan Wu and Michael S O'reilly and Robert R. Langley and Rachel Z Tsan and Cheryl H. Baker and Neby Bekele and Xi Ming Tang and Amir Onn and Isaiah J. Fidler and Roy S Herbst},
  journal={Molecular Cancer Therapeutics},
  year={2007},
  volume={6},
  pages={2652 - 2663}
}
Epidermal growth factor receptor (EGFR) has been extensively targeted in the treatment of non–small cell lung cancer, producing responses in a small number of patients. To study the role of ligand expression in mediating response to EGFR antagonism, we injected NCI-H441 [EGFR and EGF/transforming growth factor-α (TGF-α) positive] or PC14-PE6 (EGFR positive and EGF/TGF-α negative) human lung adenocarcinoma cells into the lungs of nude mice. We randomized the mice to receive treatment with the… Expand
Modification of the primary tumor microenvironment by transforming growth factor alpha-epidermal growth factor receptor signaling promotes metastasis in an orthotopic colon cancer model.
TLDR
Data show that activation of TGFalpha-EGFR signaling in colon cancer cells creates a microenvironment that is conducive for metastasis, providing a rationale for efforts to inhibit EG FR signaling in TGF alpha-positive colon cancers. Expand
Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations.
TLDR
It is shown that hepatocyte growth factor (HGF), a ligand of MET oncoprotein, induces gefitinib resistance of lung adenocarcinoma cells with EGFR-activating mutations by restoring the phosphatidylinositol 3-kinase/Akt signaling pathway via phosphorylation of MET, but not EGFR or ErbB3. Expand
Activating Mutations − Receptor Lung Adenocarcinoma with Epidermal Growth Factor Hepatocyte Growth Factor Induces Gefitinib Resistance of Updated
Lung cancer with epidermal growth factor receptor (EGFR)– activating mutations responds favorably to the EGFR tyrosine kinase inhibitors gefitinib and erlotinib. However, 25% to 30% of patients withExpand
Hepatocyte Growth Factor Reduces Susceptibility to an Irreversible Epidermal Growth Factor Receptor Inhibitor in EGFR-T790M Mutant Lung Cancer
TLDR
HGF-mediated hyposensitivity was showed as a novel mechanism of resistance to irreversible EGFR-TKIs in lung cancer harboring T790M mutation in EGFR, and it will be clinically valuable to investigate the involvement of HGF-MET–mediated signaling in de novo and acquired resistance to reversible EGFR TKIs. Expand
Differential Contribution to Neuroendocrine Tumorigenesis of Parallel Egfr Signaling in Cancer Cells and Pericytes
TLDR
This study ascribes the proangiogenic activity of Egfr in this tumor model to a novel mesenchymal Hb-egf/Egfr signaling axis, whereby endothelial and pericyte-derived Hb -egf activates Egfr specifically in tumor-associated perivascular cells, leading to increased pericytes coverage of the tumor endothelium and enhanced angiogenesis. Expand
EGFR inhibition fails to suppress vascular proliferation and tumor growth in a Ewing's sarcoma model.
TLDR
Interestingly, the resulting increase in VEGF expression following EGFR blockade, provides an alternative pro-angiogenic pathway promoting tumor survival, suggesting that angiogenesis induced by SK-NEP-1 cells is refractory to EGFR inhibition. Expand
Epidermal growth factor receptor tyrosine-kinase inhibitor treatment resistance in non-small cell lung cancer: biological basis and therapeutic strategies
TLDR
This review aims to emphasize on EGFR involved lung cancer pathway, primary and acquired mechanisms of TKIs resistance, and discuss agents currently used in clinical development in this emerging scenario. Expand
A targetable HB-EGF–CITED4 axis controls oncogenesis in lung cancer
TLDR
It is found that heparin-binding (HB)-EGF, a member of the EGF family, was highly expressed in a subset of lung cancer, proliferation of which was dependent on HB- EGF signaling, and HB-EGF provides a novel therapeutic target for lung cancer intervention. Expand
Honokiol suppresses lung tumorigenesis by targeting EGFR and its downstream effectors
TLDR
Honokiol is a promising candidate to suppress the development and even progression of lung tumors driven by EGFR deregulation and molecular docking studies indicated that honokiol binds to the tyrosine kinase domain of EGFR although it was less efficient than erlotinib. Expand
MUC1 is a downstream target of STAT3 and regulates lung cancer cell survival and invasion.
TLDR
It is demonstrated that constitutively activated STAT3 regulates expression of MUC1, which mediates lung cancer cell survival and metastasis in vitro and in vivo. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 67 REFERENCES
Dual inhibition of epidermal growth factor receptor and vascular endothelial growth factor receptor phosphorylation by AEE788 reduces growth and metastasis of human colon carcinoma in an orthotopic nude mouse model.
TLDR
Data suggest that the dual inhibition of EGFR and VEGFR signaling pathways in tumor cells and tumor-associated endothelial cells in combination with chemotherapy can provide a new approach to the treatment of colon cancer. Expand
Phosphorylated epidermal growth factor receptor on tumor-associated endothelial cells in human renal cell carcinoma is a primary target for therapy by tyrosine kinase inhibitors.
TLDR
It is suggested that the production of TGF-alpha by HRCC cells leads to the activation of EGFR on tumor-associated endothelial cells that serve as an essential target for therapy with tyrosine kinase inhibitors. Expand
Blockade of epidermal growth factor receptor signaling on tumor cells and tumor-associated endothelial cells for therapy of human carcinomas.
TLDR
Investigation of the expression of epidermal growth factor receptor (EGF-R) and activated EGF-R by tumor-associated endothelial cells is influenced by interaction with specific growth factors in the microenvironment suggests that expression of activated E GF-R is an important target for therapy. Expand
Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression.
TLDR
The association between overexpression of EGFR, TGF-alpha, or both, and overall survival of patients with resectable NSCLC, and findings suggest that this growth factor/receptor loop is more important for lung tumor formation than for tumor progression. Expand
Transforming Growth Factor α Expression Drives Constitutive Epidermal Growth Factor Receptor Pathway Activation and Sensitivity to Gefitinib (Iressa) in Human Pancreatic Cancer Cell Lines
TLDR
The data show that TGF-alpha expression identifies a subset of human pancreatic cancer cells that is dependent on EGFR signaling in vitro and in vivo and may represent an effective means of identifying EGFR-responsive primary tumors. Expand
Tumor Cell and Endothelial Cell Therapy of Oral Cancer by Dual Tyrosine Kinase Receptor Blockade
TLDR
Inhibition of EGFR and VEGFR phosphorylation by AEE788 effectively inhibits cellular proliferation of squamous cell carcinoma of the head and neck, induces apoptosis of tumor endothelial cells and tumor cells, and is well tolerated in mice. Expand
In vitro and in vivo expressions of transforming growth factor-alpha and tyrosine kinase receptors in human non-small-cell lung carcinomas.
  • C. Liu, M. Tsao
  • Biology, Medicine
  • The American journal of pathology
  • 1993
TLDR
A higher percentage of adenocarcinomas than squamous cell carcinomas over-expressed these genes, especially c-erbB-2 and c-met, which suggest a differential expression of growth factor and receptor genes among the various histological subtypes of NSCLCs. Expand
Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms.
  • C. Bruns, M. Harbison, +7 authors R. Radinsky
  • Biology, Medicine
  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2000
TLDR
Experiments indicate that therapeutic strategies targeting EGF-R have a significant antitumor effect on human L3.6pl pancreatic carcinoma growing in nude mice which is mediated in part by inhibition of tumor-induced angiogenesis, leading to tumor cell apoptosis and regression. Expand
Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells.
  • F. Ciardiello, R. Bianco, +7 authors G. Tortora
  • Biology, Medicine
  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2000
TLDR
A significant potentiation in inhibition of VEGF expression and little or no microvessels were observed in GEO tumors after the combined treatment with the two agents after the antiangiogenic and antitumor activity of monoclonal antibody C225. Expand
AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
TLDR
Data indicate that AEE788 has potential as an anticancer agent targeting deregulated tumor cell proliferation as well as angiogenic parameters, and is currently in Phase I clinical trials in oncology. Expand
...
1
2
3
4
5
...